Alnylam Pharmaceuticals Hits New 52-Week High of $485.28

Alnylam Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 485.28 on October 15, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a large-cap entity with a market capitalization of USD 59,645 million.
Over the past year, Alnylam Pharmaceuticals has demonstrated remarkable growth, with a performance increase of 206.42%, significantly outpacing the S&P 500's 13.39% gain during the same period. Despite being a loss-making company, Alnylam's price-to-book ratio stands at 238.02, indicating a premium valuation relative to its book value.

The company's financial metrics reveal a debt-to-equity ratio of -1.37 and a return on equity of -55.23%, reflecting its current financial structure and operational dynamics. With no dividend yield, Alnylam Pharmaceuticals continues to focus on its growth trajectory within the competitive landscape of the biotechnology industry. The stock's previous 52-week low was recorded at USD 205.87, highlighting the significant upward movement in its price.